Latest News and Press Releases

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments...

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overviewUpdated safety and pharmacokinetic results of...

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK)...

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment...

Erste klinische Studie untersucht Sicherheit und Immunogenität des prophylaktischen Herpes-Virus-Impfstoffkandidaten BNT163 erstmalig am MenschenBNT163 ist der erste Kandidat aus BioNTechs...

First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine...

AUSTIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro...

SURREY, British Columbia, Dec. 01, 2021 (GLOBE NEWSWIRE) -- DSG Global, Inc. (OTCQB: DSGT) ("DSGT" or the "Company") and Imperium Motor Company are pleased to announce the completion of a much...

Oakland, CA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- At the 2019 International Symposium on Neurovirology, Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases,...